Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer

Authors

Julia Foldi, Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA.Follow
Andrea Silber, Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA.Follow
Emily Reisenbichler, Department of Pathology, Yale School of Medicine, New Haven, CT, USA.Follow
Kamaljeet Singh, Department of Pathology, Yale School of Medicine, New Haven, CT, USA.Follow
Neal Fischbach, Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA.Follow
Justin Persico, Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA.Follow
Kerin Adelson, Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA.
Anamika Katoch, Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA.Follow
Nina Horowitz, Department of Surgery, Yale School of Medicine, New Haven, CT, USA.
Donald Lannin, Department of Surgery, Yale School of Medicine, New Haven, CT, USA.
Anees Chagpar, Department of Surgery, Yale School of Medicine, New Haven, CT, USA.Follow
Tristen Park, Department of Surgery, Yale School of Medicine, New Haven, CT, USA.Follow
Michal Marczyk, Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA.
Courtney Frederick, Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA.Follow
Trisha Burrello, Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA.
Eiman Ibrahim, Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA.
Tao Qing, Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA.Follow
Yalai Bai, Department of Pathology, Yale School of Medicine, New Haven, CT, USA.
Kim Blenman, Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA.Follow
David L. Rimm, Department of Pathology, Yale School of Medicine, New Haven, CT, USA.Follow
Lajos Pusztai, Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA. lajos.pusztai@yale.edu.Follow

Document Type

Article

Publication Title

NPJ breast cancer

First Page

17

DOI

10.1038/s41523-022-00392-3

Publication Date

2-3-2022

Recommended Citation

Foldi, Julia; Silber, Andrea; Reisenbichler, Emily; Singh, Kamaljeet; Fischbach, Neal; Persico, Justin; Adelson, Kerin; Katoch, Anamika; Horowitz, Nina; Lannin, Donald; Chagpar, Anees; Park, Tristen; Marczyk, Michal; Frederick, Courtney; Burrello, Trisha; Ibrahim, Eiman; Qing, Tao; Bai, Yalai; Blenman, Kim; Rimm, David L.; and Pusztai, Lajos, "Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer" (2022). Internal Medicine. 222.
https://scholar.bridgeporthospital.org/internal_medicine/222

Identifier

35115541 (pubmed); PMC8814070 (pmc); 10.1038/s41523-022-00392-3 (doi); 10.1038/s41523-022-00392-3 (pii)